Association Between Baseline Plasma Renin Activity and Clinical Outcomes in Non-Hypertensive Patients With Coronary Artery Disease: PP.24.458

Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double‐Blind Study

“…Increased baseline PRA has been associated with a greater risk of mortality in the Valsartan Heart Failure Trial (Val‐HeFT) 8 and the Heart Outcomes Prevention Evaluation (HOPE) study 9 . Elevated baseline PRA has also been associated with increased risk of cardiac events and mortality in patients with coronary artery disease 10–13 …”

“…9 Elevated baseline PRA has also been associated with increased risk of cardiac events and mortality in patients with coronary artery disease. [10][11][12][13] Aliskiren produces highly effective BP lowering as monotherapy, 14 and the combination of aliskiren with the diuretic hydrochlorothiazide (HCT) provides up to 50% greater BP reduction than HCT alone. 15 Single-pill combinations of aliskiren and HCT (aliskiren ⁄ HCT 150 ⁄ 12.5 mg, 150 ⁄ 25 mg, 300 ⁄ 12.5 mg, and 300 ⁄ 25 mg) are approved in the European Union for treating hypertension in patients whose BP is not at goal with either agent alone and in the United States for the initial treatment of hypertension in patients likely to need multiple drugs to achieve their BP goals.…”